Brainstorm Cell Therapeutics (BCLI) released its first quarter results on Tuesday, April 27, 2021. The company reported net earnings of -$0.19 per share for the first quarter ending March 31, 2021. Earnings for this past quarter were up 35 percent compared to the same period a year ago.
Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Net earnings for past trailing twelve months were -$30.36 million, down 15% from the prior year.
Moving on to the balance sheet, Brainstorm Cell Therapeutics’ cash levels jumped 188% for the third quarter over the same period last year. Overall liquidity of the balance sheet, as measured by the current ratio, increased 171.86% this past year. The current ratio for Brainstorm Cell Therapeutics now stands at 5.01. The company increased shares outstanding by 27.78%.
Shares of BCLI are currently trading around $3.53. In terms of valuation, the stock is trading at a price to book ratio of 3.49.
_____
This article was written by Value Investing News (https://www.valueinvestingnews.com) on Wednesday, April 28, 2021.